Market News

La-Z-Boy (LZB) Analysts See $0.64 EPS; Shorts at BREATHTEC BIOMEDICAL ORDINARY SHARES (BTHCF) Lowered By 11.58%

Breathtec Biomedical, Inc. (OTCMKTS:BTHCF) Logo

BREATHTEC BIOMEDICAL INC ORDINARY SHARES (OTCMKTS:BTHCF) had a decrease of 11.58% in short interest. BTHCF’s SI was 100,000 shares in May as released by FINRA. Its down 11.58% from 113,100 shares previously. With 124,500 avg volume, 1 days are for BREATHTEC BIOMEDICAL INC ORDINARY SHARES (OTCMKTS:BTHCF)’s short sellers to cover BTHCF’s short positions. The SI to BREATHTEC BIOMEDICAL INC ORDINARY SHARES’s float is 0.21%. The stock increased 3.44% or $0.0043 during the last trading session, reaching $0.1293. About shares traded. Breathtec Biomedical, Inc. (OTCMKTS:BTHCF) has 0.00% since May 18, 2017 and is . It has underperformed by 11.55% the S&P500.

Analysts expect La-Z-Boy Incorporated (NYSE:LZB) to report $0.64 EPS on June, 19.They anticipate $0.07 EPS change or 12.28% from last quarter’s $0.57 EPS. LZB’s profit would be $30.12M giving it 12.01 P/E if the $0.64 EPS is correct. After having $0.45 EPS previously, La-Z-Boy Incorporated’s analysts see 42.22% EPS growth. The stock increased 1.49% or $0.45 during the last trading session, reaching $30.75. About 285,651 shares traded. La-Z-Boy Incorporated (NYSE:LZB) has risen 8.12% since May 18, 2017 and is uptrending. It has underperformed by 3.43% the S&P500.

Breathtec Biomedical, Inc. operates as a medical diagnostics company. The company has market cap of $7.50 million. The firm focuses on developing, in-licensing, and commercializing proprietary breath analysis devices for the early detection of infections and life threatening diseases, such as cancers, liver disease, kidney failure, diabetes, asthma, tuberculosis, neurodegenerative, and others. It currently has negative earnings. It has a strategic alliance and research agreement with ZeptoMetrix Corporation to identify biomarkers associated with the Zika virus.

Among 7 analysts covering La-Z-Boy (NYSE:LZB), 2 have Buy rating, 0 Sell and 5 Hold. Therefore 29% are positive. La-Z-Boy had 15 analyst reports since August 20, 2015 according to SRatingsIntel. Barrington Research maintained La-Z-Boy Incorporated (NYSE:LZB) on Thursday, August 20 with “Outperform” rating. The firm has “Hold” rating by Stifel Nicolaus given on Tuesday, August 22. The stock of La-Z-Boy Incorporated (NYSE:LZB) earned “Hold” rating by Zacks on Tuesday, August 18. On Thursday, August 24 the stock rating was maintained by Stifel Nicolaus with “Hold”. The firm earned “Hold” rating on Thursday, November 30 by Stifel Nicolaus. BB&T Capital downgraded the stock to “Hold” rating in Wednesday, January 27 report. On Friday, August 5 the stock rating was initiated by Longbow with “Neutral”. KeyBanc Capital Markets maintained it with “Overweight” rating and $28 target in Thursday, October 6 report. As per Wednesday, September 27, the company rating was maintained by Stifel Nicolaus. The rating was initiated by Sidoti with “Buy” on Wednesday, March 2.

Another recent and important La-Z-Boy Incorporated (NYSE:LZB) news was published by which published an article titled: “La-Z-Boy Declares Quarterly Dividend” on May 01, 2018.

Since February 22, 2018, it had 0 insider buys, and 1 sale for $2.09 million activity. RICCIO LOUIS M JR also sold $2.09 million worth of La-Z-Boy Incorporated (NYSE:LZB) on Thursday, February 22.

La-Z-Boy Incorporated (NYSE:LZB) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *